Fig. 2From: Early vs. late MRD response- and risk-based treatment intensification of childhood acute lymphoblastic leukemia: a prospective pilot study from Saudi ArabiaThe 5-year overall survival (a), event-free survival (b), and cumulative incidence of relapse for the entire patient groupBack to article page